Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE PFSB to Beef Up NDA Review, Safety Measures, Victim Relief via New Drug Organization
October 6, 2003
-
ARCHIVE BULLETIN
October 6, 2003
-
ARCHIVE Revisions of Package Inserts Required for 16 Drugs, Including Ribavirin
October 6, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
October 6, 2003
-
ARCHIVE Korosho to Draft GL on Use, Management of Thalidomide
October 6, 2003
-
COLUMN Maurer's Healthcare Insight (46)
October 6, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 6, 2003
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 29, 2003
-
ARCHIVE NEW PRODUCTS
September 29, 2003
-
ARCHIVE Nihon Schering Establishing New Research Center in Kobe
September 29, 2003
-
ARCHIVE Meet the Leaders (25)
September 29, 2003
-
ARCHIVE Kurume Univ. to Begin Course in Biostatistics
September 29, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
September 29, 2003
-
ARCHIVE PRESS SEMINAR
September 29, 2003
-
ARCHIVE Boosting Awareness of Migraine Key to Maxalt Promotion: Eisai
September 29, 2003
-
ARCHIVE JACDS Proposes OTC Drug Reclassification for Sales Deregulation
September 29, 2003
-
ARCHIVE Banyu to Provide Tailor-made Evidence to Boost Nu-lotan
September 29, 2003
-
ARCHIVE Free OTC Drugs Supply via Videophone Violates PAL?
September 29, 2003
-
ARCHIVE Sales of Uralyt Could Triple to \10 Bil.: Nippon Chemiphar
September 29, 2003
-
ARCHIVE OTC NEWS IN BRIEF
September 29, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…